TITLE

Protease inhibitor

PUB. DATE
January 1996
SOURCE
Drug Topics;1/22/96, Vol. 140 Issue 2, p27
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Cites Abbott Laboratories' development of the protease inhibitor, ritonavir, to treat HIV infection. Packaging; Availability of Roche's protease inhibitor, saquinavir (Invirase) in December 1995.
ACCESSION #
9602125524

 

Related Articles

  • US Okays More Potent HIV Drug Formulation.  // Clinical Infectious Diseases;2/15/2005, Vol. 40 Issue 4, preceding p1 

    This article reports that the U.S. Food and Drug Administration has granted approval to a more potent formulation of Roche AG's HIV drug invirase, meaning that patients will not need to take as many of the pills.

  • Cancer News Round-up.  // PharmaWatch: Cancer;Mar2010, Vol. 9 Issue 3, p2 

    The article provides updates regarding the development of various pharmaceutical industries worldwide. Pfizer Inc. released a positive results from its Phase III cancer trial. Roche AB has won the approval of the European Commission for its gastric cancer drug. Moreover, Abbott Laboratories Inc....

  • Roche to boost production of HIV drug Fuzeon.  // Indianapolis Business Journal;7/21/2003, Vol. 24 Issue 19, p23 

    Reports on the plans of Roche Holding AG to produce more of the HIV drug Fuzeon in the U.S. Increase manufacturing capacity to meet demands; Trials on the efficacy of the drug in treating the disease.

  • New AIDS drug costs $56 a day. Wockner, Rex // Gay & Lesbian Times;3/6/2003, Issue 793, p31 

    Reports that Swiss drug firm Roche is making its HIV drug, the fusion inhibitor Fuzeon, available in Europe while it awaits licensing at a cost of $56 a day.

  • TYPICAL ENTRY.  // Monthly Prescribing Reference;Feb2014, Vol. 30 Issue 2, pA10 

    The article evaluates the drug Torsemide belonging to pharmacologic class Diuretic (loop) manufactured by F. Hoffmann-La Roche.

  • Halozyme Earns a $5M Launch Milestone Payment. Adamek, Steve // San Diego Business Journal;6/30/2014, Vol. 35 Issue 26, p13 

    The article reports on the $5 million milestone payment received by San Diego, California-based biopharmaceutical company Halozyme Therapeutics Inc. under an agreement with pharmaceutical company F. Hoffmann-La Roche Ltd. with the commercial launch of MabThera SC cancer therapeutic.

  • Vascular endothelial growth factor concentrations in aqueous humor before and after subconjunctival injection of bevacizumab for neovascular glaucoma. Mizote, Masanori; Baba, Tetsuya; Hirooka, Kazuyuki; Yamaji, Hidetaka; Shiraga, Fumio // Japanese Journal of Ophthalmology;May2010, Vol. 54 Issue 3, p242 

    The article reports a study that presents an alternative method of administering neovascular glaucoma (NVG) through the injection of a drug bevacizumab, trade name Avastin, developed by Roche in Basel, Switzerland. The study was performed on seven patients with NVG secondary to proliferative...

  • Avastin Fails Second Phase III Adjuvant Colon Cancer Trial.  // Bioworld Week;9/27/2010, Vol. 18 Issue 39, p3 

    The article reports that the failure of Roche AG's Phase III AVANT trial of Avastin (bevacizumab) in adjutant colon cancer is not surprising and do not raise questions since avastin is approved for late-stage colorectal, lung and kidney and breast cancer in Basel, Switzerland.

  • TYPICAL ENTRY.  // Monthly Prescribing Reference;Aug2014, Vol. 30 Issue 8, pA15 

    The article offers brief information on the drug Demadex from the firm Roche.

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics